

Supplementary Information

ATPase-dependent role of the atypical kinase Rio2 on the evolving pre-40S subunit

Sébastien Ferreira-Cerca, Vatsala Sagar, Thorsten Schäfer, Momar Diop, Anne-Maria Wesseling, Haiyun Lu, Eileen Chai, Ed Hurt and Nicole LaRonde-LeBlanc



Supplementary Figures and Tables

Supplementary Figure 1 – 5


Supplementary Table 1 and 2

Supplementary Note: Additional methods


Supplementary References




Supplementary Figure 1 | The conserved *Chaetomium thermophilum* *ctRio2* can complement a yeast *rio2Δ* mutant. (a) Multiple sequence alignment of eukaryotic Rio2 orthologs in comparison to archaeal Rio2. Sequence alignment of eukaryotic *ctRio2* (*Chaetomium thermophilum*; accession number CTHT_0033330), *scRio2* (*Saccharomyces cerevisiae*), *xRio2* (*Xenopus laevis*), *hsRio2* (*Homo sapiens*) in comparison to archaeal *afRio2* (*Archaeoglobus fulgidus*) using T-Coffee multiple sequence alignment (<http://www.ebi.ac.uk/Tools/msa/tcoffee>) and Jalview. Indicated above the alignment are the different Rio2 structural domains including wHTH, RIO domain and C-terminal extension. Moreover, the kinase catalytic residues, the flexible loop and yeast Rio2 kinase point and deletion mutations (in blue) are indicated. **(b)** *ctRio2* can complement the yeast *rio2Δ* (null) mutant. Serial dilutions of the yeast *RIO2* shuffle strain (see Supplementary Table 2) transformed either with empty plasmid (Ycplac181-ADH), *scRIO2* and *ctRIO2* under the control of the constitutive *ADH* promoter in single or high copy number (2 μ) plasmids (see Supplementary Table 3) were spotted on SDC-Leu (loading control) and SDC plates containing 5-FOA at the indicated temperature for 3 days.




Supplementary Figure 2 | Structure of the *ctRio2* kinase. (a) Comparison of the overall structure of the *ctRio2* and *afRio2* kinases. *ctRio2* is colored according to subdomain while *afRio2* is shown in grey. Loops are labeled with M, F, H, C and P for metal-binding, flexible, hinge, catalytic and phosphate-binding loops respectively. Structural differences are indicated by arrows. (b) Comparison of the structure of *ctRio2*::ATP complex with the APO structure. Very slight differences in relative positioning of the two domains and the active site loops are observed, indicated by arrows. (c) Close-up of *ctRio2* active site showing differences in positioning of metal ions and phosphates in *afRio2*. (d) Electron density map calculated with ATP modeled in the *ctRio2* active site. Density in blue is 2Fo-Fc contoured at 1 σ , and in red and green is Fo-Fc negative and positive difference density, respectively, contoured at 3 σ . The yellow stick model is the model as is currently, after fitting a phosphoaspartate in place of the ATP γ -phosphate. (e) Fo-Fc difference density calculated after deletion of the phosphate group on top of the final model. Density is shown as in d.



Supplementary Figure 3 | *ctRio2* ATPase activity and nucleotide binding. (a, b) the amount of released free phosphate (P_i) was analyzed in single-turnover experiments in presence of the indicated amount of purified recombinant protein and 50 nM ATP/ γ^{32} P-labeled ATP (see Online Methods). Reactions were stopped at the indicated time points. ATP and P_i were separated by thin-layer chromatography and quantified with ImageJ. (a) *ctRio2* protein concentration-dependent P_i release (ATPase activity) was performed with the indicated amount of purified *ctRio2* (b) analysis of free P_i released in the presence of 1 μ M purified *ctRio2* wild-type and mutants. (c) nucleotide binding was examined by measuring the change of fluorescence intensity (in arbitrary units) of mant-ATP (λ_{ex} - 355 nm, λ_{emax} - 440 nm) upon protein binding (see Supplementary Note). The intrinsic fluorescence by mant-ATP (no protein-black curve) is enhanced after the addition of *ctRio2* (red curve).



Supplementary Figure 4 | Fitting of the eukaryotic Rio2 into cryo-EM density from yeast pre-40S particles. **(a)** Difference density (green mesh) resulting from subtraction of cryo-EM density of the TAP-tagged Rio2-containing and Rio2-depleted pre-40S particles (grey solid). The main domains of the ribosome are labeled and assignment of difference density is identified as in Strunk et al^{1,2}. **(b)** Best rigid body fit of *ct*Rio2 in the Rio2 difference density. Domains are labeled to provide orientation. **(c)** Fit of the molecule in two different orientations, rotated 180° around the vertical and horizontal axes. Both resulted in slightly lower correlation coefficients (CC; calculated in Chimera¹). **(d)** Overlay of Molecular Dynamic Flexible Fit (MDFF)³ model (blue) on starting model (yellow; same as in a). **(e)** Plot of RMSD's for all molecules in the MDFF trajectory relative to the starting model shows convergence after ~200 frames (200 ps). **(f)** Alignment of the C-terminal lobes of the *ct*Rio2::ATP complex (colored according to domains) and that of the MDFF model (grey) shows significant shift of the N-terminal lobe and the wHTH domains. The distance between the catalytic (C) and the phosphate-binding (P) loops increases by 1.6 Å, and there is a ~ 5.6 Å shift of the wHTH domain (measured by the change in distance between equivalent atoms in helices 2 and 3 of the domain).



Supplementary Figure 5 | Rio2 functional domain organization and generation of Hrr25 and Rio2 ATP-analogue sensitive strains. (a) scRio2 wHTH domain and eukaryotic C-terminal extension are essential for viability. The indicated Rio2 alleles were tested for complementation of *rio2Δ* (null) by shuffling experiment on SDC plus 5-FOA at 23°C, 30°C and 37°C. +++, complementation at tested temperatures (23, 30, 37°C); -, no complementation (23, 30, 37°C). (b) Most of the Rio2 eukaryotic specific C-terminal part is not essential for cell growth in the

presence of *LTV1*⁺. Serial dilutions of the yeast *RIO2* shuffle strain wild-type or deleted for *Ltv1* (see Supplementary Table 2) transformed either with empty plasmid (pRS315), *scRIO2* full-length or different C-terminal deletions were spotted on SDC-Leu (loading control) and SDC plates containing 5-FOA at the indicated temperature for 3 days. **(c)** Overview of the strategy to generate ATP-analogue sensitive protein kinases (see also Supplementary Note). Wild-type kinases contain a conserved “gate-keeper” residue(s) restricting access of bulky ATP-analogs to the ATP-binding pocket (left side). ATP-analogue-sensitive kinases are mutated to enlarge the ATP-binding pocket allowing accommodating of bulky ATP-derivatives (right side). **(d)** Chemical formula of the ATP-analogues CZ14 and 3MB-PP1 used to inhibit *hrr25* I82A and *rio2* V121A M189G kinases, respectively. **(e)** Structural model of *ctRio2* V122A M189G (or orthologous *scRio2* V121A M189G). Mutations of residues V122A and M189G were directly introduced into the structure of *ctRio2*::ATP using the mutagenesis tool of PyMol. Note that the corresponding mutations enlarge the ATP-binding pocket allowing simulated binding of an bulky ATP-analogue. **(f)** *in vivo* inhibition of *rio2* V121A M189G carrying cells in presence of 3MB-PP1. Serial dilutions of yeast strains expressing wild-type *RIO2* or mutants *rio2* were spotted on YPD plates containing either 0.5% DMSO (mock control) or indicated amount of 3MB-PP1 (solved in DMSO) and incubated at the indicated temperatures for 3 days. **(g)** *in vivo* inhibition of *hrr25* I82G carrying cells in presence of CZ14. Serial dilutions of yeast strains expressing wild-type *HRR25* or mutant *hrr25* I89G were spotted on YPD plates containing either 0.25% DMSO (mock control) or indicated amount of CZ14 (solved in DMSO) and incubated at the indicated temperatures for 2 days.

Supplementary Table 1 | List of strains used in this study.

Strain	Genotype	Plasmid	Origin
BY4741/WT	Mat <i>a</i> ; his3 Δ ; leu2 Δ ; met15 Δ ; ura3 Δ		Euroscarf
rio2 Δ /RIO2 diploid	BY4743 Mat <i>a</i> / α ; his3 Δ /his3 Δ ; leu2 Δ /leu2 Δ ; LYS2/ lys2 Δ ; MET15/met15 Δ ; ura3 Δ /ura3 Δ ; YNL207w/ YNL207w::kanMX4		Euroscarf
RIO2 shuffle strain	Mat <i>a</i> ; his3 Δ ; leu2 Δ ; lys2 Δ ; met15 Δ ; ura3 Δ ; YNL207w::kanMX4	pURA3-RIO2-GFP	this work: derived from rio2 Δ /RIO2 diploid
RIO2 shuffle strain Itv1 Δ	his3 Δ ; leu2 Δ ; ura3 Δ ; YNL207w::kanMX4; YKL143W::kanMX4	pURA3-RIO2-GFP	this work; offspring from crossing RIO2 shuffle strain with BY4742 Itv1 Δ (Euroscarf)
RIO2 shuffle strain, Enp1-TAP	Mat <i>a</i> ; his3 Δ ; leu2 Δ ; lys2 Δ ; met15 Δ ; ura3 Δ ; YNL207w::kanMX4; ENP1-TAP::His3MX6	pURA3-RIO2-GFP	this work; derived from RIO2 Shuffle strain
RIO2 shuffle strain, Ltv1-TAP	Mat <i>a</i> ; his3 Δ ; leu2 Δ ; lys2 Δ ; met15 Δ ; ura3 Δ ; YNL207w::kanMX4; LTV1-TAP::His3MX6	pURA3-RIO2-GFP	this work; derived from RIO2 shuffle strain
RIO2 shuffle strain, Tsr1-TAP	Mat <i>a</i> ; his3 Δ ; leu2 Δ ; lys2 Δ ; met15 Δ ; ura3 Δ ; YNL207w::kanMX4; TSR1-TAP::His3MX6	pURA3-RIO2-GFP	this work; derived from RIO2 shuffle strain
HRR25 shuffle strain	his3 Δ ; leu2 Δ ; ura3 Δ ; YPL204w::kanMX4	pURA3-HRR25	this work
HRR25 shuffle strain, Ltv1-TAP	his3 Δ ; leu2 Δ ; ura3 Δ ; YPL204w::kanMX4; LTV1-TAP::His3MX6	pURA3-HRR25	this work

Supplementary Table 2 | List of plasmids used in this study.

Plasmid	Features	Origin
pRS315-RIO2	CEN; LEU2; RIO2 ORF including 500nt before ATG and 140nt after stop codon	this study
pRS315-rio2-1	CEN; LEU2; rio2 mutant ORF including 500nt before ATG and 140nt after stop codon	ref. ⁴
pRS315-rio2 V121A M189G	CEN; LEU2; rio2 mutant ORF including 500nt before ATG and 140nt after stop codon	this study
pRS315-rio2 K123A	CEN; LEU2; rio2 mutant ORF including 500nt before ATG and 140nt after stop codon	this study
pRS315-rio2 D229A	CEN; LEU2; rio2 mutant ORF including 500nt before ATG and 140nt after stop codon	this study
pRS315-rio2 D253A	CEN; LEU2; rio2 mutant ORF including 500nt before ATG and 140nt after stop codon	this study
pRS315-rio2 Δ 129-146	CEN; LEU2; rio2 mutant ORF including 500nt before ATG and 140nt after stop codon	this study
pRS315-rio2 Δ 131-146	CEN; LEU2; rio2 mutant ORF including 500nt before ATG and 140nt after stop codon	this study
pRS315-rio2 neutral loop (R129A/ H133A/ R136A/ R139A/ D140A/ K143A/ K144A)	CEN; LEU2; rio2 mutant ORF including 500nt before ATG and 140nt after stop codon	this study
pRS315-rio2 Δ 87-425	CEN; LEU2; rio2 mutant ORF including 500nt before ATG and 140nt after stop codon	this study
pRS315-rio2 Δ 2-86	CEN; LEU2; rio2 mutant ORF including 500nt before ATG and 140nt after stop codon	this study
pRS315-rio2 Δ 1-315	CEN; LEU2; rio2 mutant ORF including 500nt before ATG and 140nt after stop codon	this study
pRS315- rio2 Δ 356-425	CEN; LEU2; rio2 mutant ORF including 500nt before ATG and 140nt after stop codon	this study
pRS315- rio2 Δ 335-425	CEN; LEU2; rio2 mutant ORF including 500nt before ATG and 140nt after stop codon	this study
pRS315- rio2 Δ 328-425	CEN; LEU2; rio2 mutant ORF including 500nt before ATG and 140nt after stop codon	this study
pRS315-rio2 Δ 315-425	CEN; LEU2; rio2 mutant ORF including 500nt before ATG and 140nt after stop codon	this study
pRS315-HRR25	CEN; LEU2; HRR25 ORF including 880nt before ATG and 865nt after stop codon	this study
pRS315-hrr25 I82G	CEN; LEU2; hrr25 I82G ORF including 880nt before ATG and 865nt after stop codon	this study
pRS315-RIO2-GFP	CEN; LEU2; RIO2 ORF including 500nt before ATG and 140nt after stop codon	ref. ⁴
Ycplac111-RIO2-TAP	CEN; LEU2; RIO2 ORF without stop codon fused to the TAP-tag including 500nt before ATG codon	this study
Ycplac111-rio2 D253A-TAP	CEN; LEU2; rio2 D253A ORF without stop codon fused to the TAP-tag including 500nt before ATG codon	this study
Ycplac111-rio2 neutral loop-TAP	CEN; LEU2; rio2 loop mutant ORF without stop codon fused to the TAP-tag including 500nt before ATG codon	this study

Ycplac111-rio2 K105E-TAP	CEN; LEU2; rio2 loop mutant ORF without stop codon fused to the TAP-tag including 500nt before ATG codon	this study
YEP352-GAL::RIO2	2 μ ; URA3; RIO2 ORF under GAL promoter	this study
YEP352-GAL::rio2 D253A	2 μ ; URA3; RIO2 ORF under GAL promoter	this study
YEP352-GAL::rio2 neutral loop	2 μ ; URA3; RIO2 ORF under GAL promoter	this study
YEP352-GAL::rio2 D253A + neutral loop	2 μ ; URA3; RIO2 ORF under GAL promoter	this study
Ycplac111-ADH::scRIO2	CEN; LEU2; ADH promoter; scRIO2	this study
Ycplac111-ADH::ctRIO2	CEN; LEU2; ADH promoter; ctRIO2	this study
Ycplac181-ADH::scRIO2	2 μ ; LEU2; ADH promoter; scRIO2	this study
Ycplac181-ADH::ctRIO2	2 μ ; LEU2; ADH promoter; ctRIO2	this study
pT7::His6-TEV-ctRIO2	E.coli expression vector; Amp	this study
pT7::His6-TEV-ct rio2 D229A	E.coli expression vector; Amp	this study
pT7::His6-TEV-ct rio2 D257A	E.coli expression vector; Amp	this study
pT7::His6-TEV-ct rio2 K106E	E.coli expression vector; Amp	this study
pT7::His6-TEV-ct rio2 K124A	E.coli expression vector; Amp	this study
pT7::His6-TEV-ct rio2 „neutral loop“ (R130A/ R134A/ K137A/ R140A/ D141A/ R144A/ R146A)	E.coli expression vector; Amp	this study

Supplementary Note: Additional methods

Generation of ATP-analogue sensitive yeast strains. In order to sensitize the Hrr25 and Rio2 kinases to ATP-analogues, a conserved gate-keeper residue mutation, *hrr25* I82G and *rio2* M189G, was introduced as previously described⁵. A series of individual 4-amino-1-*tert*-butyl-pyrazolo[3,4-*d*]pyrimidine derivatives was assayed for growth retardation of *hrr25* I82G and *rio2* M189G using filter assays. The structurally related compounds CZ14, CZ31 and CZ32 were found to be the most potent inhibitor of *hrr25* I82G. Concentration from 1-10 μ M of CZ14 effectively inhibited proliferation of *hrr25* I82G mutant cells, but was fully tolerated by the respective wild-type strain. In contrast to *hrr25* I82G cells, only slight cell growth retardation was observed with substances 3MB-PP1, 1NMPP1, 2MeNAPP1, CZ22, and PP1 in the case of the *rio2* M189G mutant. In order to further sensitize the Rio2 kinase we performed a second site mutagenesis (V121A), predicted to enlarge further the ATP-binding pocket. Reduction in cell growth of *rio2* V121A M189G in response to 3MB-PP1 at lower temperature was observed at concentration ranging from 5-25 μ M without affecting wild-type cell growth. For further information, see also Supplementary Fig. 5.

Purification of recombinant *ctRio2* and *ctHrr25* for single turnover and ATP binding assays. Recombinant *ctRio2* wild-type or mutant proteins were expressed overnight in LB medium containing 100 μ g/ml ampicillin and 0.3 mM IPTG at 18°C. *ctHrr25* was expressed overnight in M9 minimal medium containing 30 μ g/ml kanamycin and 0.3 mM IPTG at 18°C. Cells expressing *ctRio2* and *ctHrr25* were resuspended in buffer K200 (10% Glycerol, 20 mM Tris-HCl pH 7.5, 200 mM KCl, 10 mM imidazole, 5 mM MgCl₂, 2 mM β -mercaptoethanol) and K1500 (same as K200 but with 1.5 M KCl) respectively, and lysed using a microfluidiser. Homogenates clarified by centrifugation at 14,000g for 20 min at 4°C were added to pre-equilibrated Talon-beads (Clontech) (in 0.1% NP-40 and buffer K200 or K1500) and incubated on a rotating wheel for 90 min at 4°C. Beads were washed in batch 4 times 20 min with 20 ml buffer at 4°C, and 3 times 20 ml by gravity flow on a Bio-Rad chromatography column. Proteins were eluted with K200 or K1500 buffer containing 220 mM imidazole. Prior to buffer exchange and concentration the eluted *ctHrr25* was incubated overnight at 4°C, and centrifuged for 20 min at 14,000 rpm at 4°C on a bench-top centrifuge. Eluted proteins were buffer

exchanged and concentrated using a Centricon filter (30 kDa cut-off; Millipore) to 50 μ M in buffer K200.

Phosphate release quantification. To estimate the amount of *ctRio2* phosphorylation, a 50 nM ATP/ γ - 32 P-labeled ATP standard (100% - 0.01%) was spotted on TLC plates, dried and exposed overnight on a Phosphorimager screen. Since the overall amount of γ - 32 P-ATP used for *ctRio2* auto-phosphorylation was estimated being below 0.1% of the total hydrolysis events, this event was neglected from further quantification.

All quantifications of TLC plates were performed using ImageJ. For every time point the amount of ATP and P_i were determined after subtraction of background. Assuming that most of the hydrolyzed ATP is converted into free phosphate the sum of ATP and P_i radioactivity (in this case phosphorylation of Rio2 is negligible) at different time points represents 100% of the radioactivity loaded on the TLC plate for this time point. Therefore the amount of free phosphate released can be determined for every time points using the following formula:

$$(P_i \text{ in } \%)_{tx} = P_{i_{tx}} / (ATP_{tx} + P_{i_{tx}}) \times 100$$

Since for *ctHrr25* the amount of ATP is reduced overtime and converted into phosphorylated substrate, the amount of ATP at $t=0$ was used as normalization constant :

$$(ATP_{t0}=100\%). (P_i \text{ in } \%)_{tx} = P_{i_{tx}} / (ATP_{t0} + P_{i_{tx}}) \times 100.$$

ATP-binding experiments. Reactions (100 μ l) were performed in 96 well-plate, were 1 μ M of the indicated recombinant proteins was incubated with 0.5 μ M of Mant-ATP (Jena bioscience) in buffer K200 for 20 min at 30°C. The mant-ATP was excited at 355 nm with a xenon lamp, and emission spectra were recorded between 385-600 nm with a 5 nm increment step using a Synergy 4 spectrophotometer (BioTek).

In vitro phosphorylation assay on isolated pre-40S. Tandem affinity purified pre-40S particles isolated using Ltv1-TAP as a bait were first pre-incubated for 15 min at 23°C in presence of 5 μ M CZ14 (specific for *hrr25* I82G), 25 μ M 3MB-PP1 (specific for *rio2* V121A M189G) or in mock-buffer (DMSO). *In vitro* phosphorylation was induced by addition of a mixture of radioactive γ - P^{32} ATP/ATP (1/1000) for 30 min at 23°C. The γ - P^{32} labeled pre-40S particles were analyzed by SDS-PAGE/Coomassie staining, followed by

autoradiography of dried gels.

Miscellaneous. Polysome profiles and monosomes were analysed by sucrose gradient centrifugation as previously described⁶. Affinity-purifications of TAP-tagged bait proteins were, unless otherwise indicated, performed in a buffer containing 50 mM Tris-HCl, pH 7.5, 100 mM NaCl, 1.5 mM MgCl₂, 5% glycerol, and 0.1% NP-40 essentially as described previously^{6,7}. For tobacco etch virus (TEV) protease cleavage, DTT and Rnasin (Fermentas) was added to the buffer to a final concentration of 1 mM and 200 U/ml, respectively. Elution from Calmodulin–Sepharose beads was performed for 20 min at 30°C in the presence of 5 mM EGTA. The EGTA eluates were precipitated by the addition of TCA and dissolved in SDS-sample buffer (10-fold concentrated), before separation on NuPAGE SDS 4–12% gradient polyacrylamide gels (Invitrogen) and staining with colloidal Coomassie (Sigma-Aldrich). Mass spectrometry identification of the proteins contained in Coomassie-stained bands was performed as described previously⁷. Western blot analysis was performed using the following primary antibodies: anti-Rio2 (Santa-Cruz, Rio2 Y-220, cat. no. sc-98828; 1:500), anti-ProtA (Sigma, cat. no. P1291; 1:10,000), anti-HA (Covance, cat. no. MMS101R; 1:1,000), anti-rpS3⁸ (1:5,000), anti-rpS8⁸ (1:8,000), anti-Tsr1² (1:1,000) and anti-Arc1⁹ (1:5,000). Horseradish peroxidase conjugated goat anti-rabbit (Roche, cat. no. 170-6515; 1:8,000) and goat anti-mouse (Bio-Rad, cat. no. 170-6516; 1:3,000) were used as secondary antibodies.

Supplementary References

1. Pettersen, E.F. et al. UCSF Chimera--a visualization system for exploratory research and analysis. *J Comput Chem* **25**, 1605-12 (2004).
2. Strunk, B.S. et al. Ribosome assembly factors prevent premature translation initiation by 40S assembly intermediates. *Science* **333**, 1449-53 (2011).
3. Trabuco, L.G., Villa, E., Mitra, K., Frank, J. & Schulten, K. Flexible fitting of atomic structures into electron microscopy maps using molecular dynamics. *Structure* **16**, 673-83 (2008).
4. Schäfer, T., Strauss, D., Petfalski, E., Tollervey, D. & Hurt, E.C. The path from nucleolar 90S to cytoplasmic 40S pre-ribosomes. *EMBO J.* **22**, 1370-1380 (2003).
5. Blethrow, J., Zhang, C., Shokat, K.M. & Weiss, E.L. Design and use of analog-sensitive protein kinases. *Curr Protoc Mol Biol* **Chapter 18**, Unit 18 11 (2004).
6. Kressler, D., Roser, D., Pertschy, B. & Hurt, E. The AAA ATPase Rix7 powers progression of ribosome biogenesis by stripping Nsa1 from pre-60S particles. *J Cell Biol* **181**, 935-44 (2008).
7. Nissan, T.A., Bassler, J., Petfalski, E., Tollervey, D. & Hurt, E. 60S pre-ribosome formation viewed from assembly in the nucleolus until export to the cytoplasm. *EMBO J* **21**, 5539-47 (2002).
8. Schafer, T. et al. Hrr25-dependent phosphorylation state regulates organization of the pre-40S subunit. *Nature* **441**, 651-5 (2006).
9. Simos, G., Sauer, A., Fasiolo, F. & Hurt, E.C. A conserved domain within Arc1p delivers tRNA to aminoacyl-tRNA synthetases. *Mol Cell* **1**, 235-42 (1998).